CN1297265C - 抗血栓形成药与阿司匹林的新组合及其在制备用于治疗动脉粥样硬化血栓形成性疾病的药物中的用途 - Google Patents

抗血栓形成药与阿司匹林的新组合及其在制备用于治疗动脉粥样硬化血栓形成性疾病的药物中的用途 Download PDF

Info

Publication number
CN1297265C
CN1297265C CNB038078619A CN03807861A CN1297265C CN 1297265 C CN1297265 C CN 1297265C CN B038078619 A CNB038078619 A CN B038078619A CN 03807861 A CN03807861 A CN 03807861A CN 1297265 C CN1297265 C CN 1297265C
Authority
CN
China
Prior art keywords
aspirin
formula
compound
chemical compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038078619A
Other languages
English (en)
Chinese (zh)
Other versions
CN1646111A (zh
Inventor
T·韦伯朗
G·拉维埃勒
B·西默蒂埃
M-O·瓦莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of CN1646111A publication Critical patent/CN1646111A/zh
Application granted granted Critical
Publication of CN1297265C publication Critical patent/CN1297265C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB038078619A 2002-04-05 2003-04-04 抗血栓形成药与阿司匹林的新组合及其在制备用于治疗动脉粥样硬化血栓形成性疾病的药物中的用途 Expired - Fee Related CN1297265C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204222A FR2838057B1 (fr) 2002-04-05 2002-04-05 Nouvelle association d'un antithrombotique et d'aspirine
FR02/04222 2002-04-05

Publications (2)

Publication Number Publication Date
CN1646111A CN1646111A (zh) 2005-07-27
CN1297265C true CN1297265C (zh) 2007-01-31

Family

ID=28052120

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038078619A Expired - Fee Related CN1297265C (zh) 2002-04-05 2003-04-04 抗血栓形成药与阿司匹林的新组合及其在制备用于治疗动脉粥样硬化血栓形成性疾病的药物中的用途

Country Status (26)

Country Link
US (1) US7618955B2 (enExample)
EP (1) EP1496884B1 (enExample)
JP (1) JP4065853B2 (enExample)
KR (1) KR100645143B1 (enExample)
CN (1) CN1297265C (enExample)
AR (1) AR039253A1 (enExample)
AT (1) ATE329591T1 (enExample)
AU (1) AU2003246774B2 (enExample)
BR (1) BR0309019A (enExample)
CA (1) CA2480697A1 (enExample)
CY (1) CY1105106T1 (enExample)
DE (1) DE60306133T2 (enExample)
DK (1) DK1496884T3 (enExample)
EA (1) EA006978B1 (enExample)
ES (1) ES2264533T3 (enExample)
FR (1) FR2838057B1 (enExample)
GE (1) GEP20074101B (enExample)
MA (1) MA27114A1 (enExample)
MX (1) MXPA04009760A (enExample)
NO (1) NO20044700L (enExample)
NZ (1) NZ535430A (enExample)
PL (1) PL371620A1 (enExample)
PT (1) PT1496884E (enExample)
UA (1) UA79457C2 (enExample)
WO (1) WO2003084525A1 (enExample)
ZA (1) ZA200407593B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMP200800012B (it) * 2005-07-22 2008-02-27 Procter & Gamble Composizioni per ridurre l'incidenza di aritmia indotta da farmaco
CN103071154A (zh) 2007-04-13 2013-05-01 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
JP2009001537A (ja) * 2007-06-25 2009-01-08 Lab Servier 血管障害の処置を目的とする医薬の入手における抗アテローム血栓化合物の使用
FR2920772B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472979A (en) * 1993-10-15 1995-12-05 Adir Et Compagnie 1,2,3,4-tetrahydronaphthalene compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472979A (en) * 1993-10-15 1995-12-05 Adir Et Compagnie 1,2,3,4-tetrahydronaphthalene compounds

Also Published As

Publication number Publication date
US7618955B2 (en) 2009-11-17
UA79457C2 (en) 2007-06-25
EP1496884A1 (fr) 2005-01-19
NZ535430A (en) 2006-09-29
FR2838057A1 (fr) 2003-10-10
BR0309019A (pt) 2005-02-01
FR2838057B1 (fr) 2005-07-08
MA27114A1 (fr) 2004-12-20
DK1496884T3 (da) 2006-10-02
EA006978B1 (ru) 2006-06-30
ATE329591T1 (de) 2006-07-15
CY1105106T1 (el) 2009-11-04
PL371620A1 (en) 2005-06-27
ES2264533T3 (es) 2007-01-01
EP1496884B1 (fr) 2006-06-14
EA200401293A1 (ru) 2005-02-24
AU2003246774A1 (en) 2003-10-20
MXPA04009760A (es) 2004-12-13
AR039253A1 (es) 2005-02-16
GEP20074101B (en) 2007-05-10
NO20044700L (no) 2004-10-29
HK1076034A1 (en) 2006-01-06
WO2003084525A1 (fr) 2003-10-16
ZA200407593B (en) 2006-07-26
AU2003246774B2 (en) 2007-02-15
PT1496884E (pt) 2006-09-29
JP2005528376A (ja) 2005-09-22
DE60306133T2 (de) 2007-01-04
US20050143354A1 (en) 2005-06-30
KR100645143B1 (ko) 2006-11-10
KR20040098053A (ko) 2004-11-18
DE60306133D1 (de) 2006-07-27
CN1646111A (zh) 2005-07-27
CA2480697A1 (fr) 2003-10-16
JP4065853B2 (ja) 2008-03-26

Similar Documents

Publication Publication Date Title
US20220193087A1 (en) Combination therapies for the treatment of alzheimer's disease and related disorders
WO2010071866A2 (en) Combination therapy for arthritis with tranilast
AU2019327262B2 (en) Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor
CN1297265C (zh) 抗血栓形成药与阿司匹林的新组合及其在制备用于治疗动脉粥样硬化血栓形成性疾病的药物中的用途
JPWO2011059053A1 (ja) 糖尿病の治療または予防薬
JP2005528376A5 (enExample)
KR100782246B1 (ko) 항혈전제와 항혈소판 응집제의 조합체
HK1076034B (en) Novel association of an antithrombotic agent with aspirin and use thereof for the manufacture of a medicament for treating atherothrombotic diseases
JPH0410446B2 (enExample)
JPS59137451A (ja) インダン誘導体
HK1093900B (en) Novel association consisting of an anti-atherothrombotic agent and of a platelet antiaggregating agent
CN115397404A (zh) 用于治疗covid-19的cxcl8抑制剂
JP2007508242A (ja) トロンボキサンａ２受容体アンタゴニストとシクロオキシゲネーゼ−１の阻害剤との組み合わせを伴う組成物および方法
IES83242Y1 (en) Inhibition of platelet aggregation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076034

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070131

Termination date: 20100404